Nano carriers that enable co-delivery of chemotherapy and RNAi agents for treatment of drug-resistant cancers
- Title
- Nano carriers that enable co-delivery of chemotherapy and RNAi agents for treatment of drug-resistant cancers
- Authors
- Vasilios Tsouris; 주민경; 김선화; 권익찬; 원유연
- Keywords
- Cancer; Drug resistance; Chemotherapy; RNA interference; Combination therapy; Co-delivery
- Issue Date
- 2014-09
- Publisher
- Biotechnology advances
- Citation
- VOL 32, 1037-1050
- Abstract
- Tumor cells exhibit drug resistant phenotypes that decrease the efficacy of chemotherapeutic treatments. The
drug resistance has a genetic basis that is caused by an abnormal gene expression. There are several types of
drug resistance: efflux pumps reducing the cellular concentration of the drug, alterations in membrane lipids
that reduce cellular uptake, increased or altered drug targets,metabolic alteration of the drug, inhibition of apoptosis,
repair of the damaged DNA, and alteration of the cell cycle checkpoints (Gottesman et al., 2002; Holohan
et al., 2013). siRNA is used to silence the drug resistant phenotype and prevent this drug resistance response. Of
the listed types of drug resistance, pump-type resistance (e.g., high expression of ATP-binding cassette transporter
proteins such as P-glycoproteins (Pgp; also known asmulti-drug resistance protein 1 orMDR1, encoded by the
ATP-Binding Cassette Sub-Family B Member 1 (ABCB1) gene)) and apoptosis inhibition (e.g., expression of antiapoptotic
proteins such as Bcl-2) are the most frequently targeted for gene silencing. The co-delivery of siRNA
and chemotherapeutic drugs has a synergistic effect, butmany of the current projects do not control the drug release
fromthe nanocarrier. This means that the drug payload is released before the drug resistance proteins have
degraded and the drug resistance phenotype has been silenced. Current research focuses on cross-linking the
carrier's polymers to prevent premature drug release, but these carriers still rely on environmental cues to release
the drug payload, and the drugmay be released too early. In this review, we studied the release kinetics of siRNA
and chemotherapeutic drugs from a broad range of carriers.We also give examples of carriers used to co-deliver
siRNA and drugs to drug-resistant tumor cells, and we examine howmodifications to the carrier affect the delivery.
Lastly, we give our recommend
- URI
- https://pubs.kist.re.kr/handle/201004/48739
- ISSN
- 07349750
- Appears in Collections:
- KIST Publication > Article
- Files in This Item:
There are no files associated with this item.
- Export
- RIS (EndNote)
- XLS (Excel)
- XML
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.